Spark’s blindness gene therapy reviewed by US FDA – Reuters
|
Spark's blindness gene therapy reviewed by US FDA
Reuters Oct 10 (Reuters) – Spark Therapeutics Inc's experimental gene therapy for a rare inherited form of blindness is effective, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration. |
